To identify key predictors of RFS in melanoma patients receiving IFN-α1b adjuvant therapy, we performed the time-dependent feature importance analysis, including tumor characteristics (site and stage), patient demographics (age and sex), comorbidities (diabetes mellitus, hypertension and hepatitis B virus) and various laboratory indices (neutrophil (NEU), alanine aminotransferase, aspartate aminotransferase, lymphocyte, hemoglobin (Hb), albumin (ALB), white blood cell, platelet and alkaline phosphatase) (Supplementary Figure 1). The gene discussed is GSTM1; the disease is neoplasm.